An observational study in Metabolic Dysfunction-steatohepatitis (MASH), sponsored by Radnet Management, Inc.. Not yet recruiting at 3 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Radnet Management, Inc. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 212 studies in Fatty Liver with a site in United States — 42 open to participants now, 48 under way, 8 of them phase 3. Fatty Liver · United States.
Among the 212 studies in Fatty Liver with a site in United States, this one is the 6th largest by planned enrollment of the 48 observational ones that give a count, is one of 15 that started in 2026, is one of 48 observational ones, reaches primary completion later than 32 of the 47 other live ones, and was the 210th registered.
666 studies on the registry are indexed under Fatty Liver; 188 are open to participants now.
Browse Fatty Liver studies →42 of the 212 studies in Fatty Liver with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
Madrigal Pharmaceuticals, Inc. · Sites in United States
Ages 18+
Madrigal Pharmaceuticals, Inc. · Sites in United States
Ages 18+
Kriya Therapeutics, Inc. · Sites in United States, New Zealand
Ages 18–75
Altimmune, Inc. · Sites in United States, Puerto Rico
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 118 Fatty Liver studies recruiting now, 36 (31%) set no upper age limit and 63 (53%) stop at 75 or younger; 8 take children under 18; 32 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
212 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 31 · Phase 2 57 · Phase 3 17 · Phase 4 12
First in 2001; this study’s year is marked. 15 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 524 is above the median of 150 across 207 observational studies indexed under Fatty Liver.
Median enrollment 44 across the 163 interventional studies, 85 across the 48 observational. Of the 149 that completed or were terminated, 63 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
61 of 212 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Radnet Management, Inc. as lead sponsor.
Radnet Management, Inc. has 1 study filed under Fatty Liver — fewer than ten, so there is no comparison to draw.
14 of the studies in Fatty Liver with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06354088Columbia UniversityHuman Models of Selective Insulin Resistance: Alpelisib, Part I | 2026-12-31 |
| NCT04781322National Institute on Alcohol Abuse and Alcoholism (NIAAA)Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy Drinkers | 2026-12-31 |
| NCT06944353Northwestern UniversityImproving Diagnostic Safety Through STeatosis Identification, Risk Stratification, and Referral in the ED | 2027-01 |
| NCT07491458Rivus Pharmaceuticals, Inc.A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH) | 2027-02 |
| NCT07946341Cascade Pharmaceuticals, IncA Study in Healthy Participants With Elevated LDL-C to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS060380 | 2027-03-15 |
Add all 14 to your calendar (.ics) → With an account.
Among the 212 studies in Fatty Liver with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective, non-interventional, observational study to evaluate the accuracy of 2 US (ultrasound) biomarkers that quantify liver tissue fat and stiffness: UDFF (ultrasound-derived fat fraction) and pSWE (point shear wave elastography) for determining MRI-defined eligibility for resmetirom (REZDIFFRA®) treatment and for monitoring treatment response using MRI-PDFF (proton density fat fraction) and MRE (magnetic resonance elastography) as reference standards.
Study Centers Planned:
3 clinical practice facilities in Houston TX .
Study Rationale:
MASLD (metabolic dysfunction-associated steatotic liver disease ) is a growing global epidemic and the most common liver disease worldwide. Approximately 25% of adults in the United States alone have hepatic steatosis in the absence of significant alcohol consumption and 1 in 4 of these adults are presumed to have MASH.
MASH has a higher likelihood of progression to irreversible liver damage including cirrhosis and hepatocellular carcinoma.
Despite advancements in the field, there is still a high unmet need for technologies to accurately and reliably grade liver steatosis and stage liver fibrosis for applications related to patient identification and monitoring response to therapeutic intervention.
The association between hepatic steatosis and fibrosis progression underscores the need to have accurate and reliable noninvasive tools to aid in the assessment and monitoring of both liver steatosis and fibrosis.
The combination of 2 US (ultrasound) biomarkers that quantify liver tissue fat and stiffness (UDFF and pSWE) may aid clinicians in streamlining patient care pathways and potentially avoid unwanted and invasive medical intervention.
This study will consist of 3 phases:
A Pilot Study will be conducted before the Main Study to verify image acquisition quality and data completeness, and to assess repeatability (US) and reproducibility (US and MRI). The Pilot Study will include 24 adult participants (n=8 participants/site across 3 imaging centers).
Each participant in the pilot study will undergo 4 US (ultrasound) scans (2 scans each by 2 Certified US Technologists).
All US scans will be performed on SIEMENS ACUSON Sequoia systems using the 5C1 transducer and the same software version throughout the study. Repeated US scans will be separated by ≥5 minutes, with participants repositioned between scans by the Certified US Technologists.
Each participant in the pilot study will also undergo 2 MRI scans (1 scan each by 2 Certified MRI Technologists):
MR scans will be performed using either the SIEMENS MAGNETOM Skyra 3T or GE SIGNA PIONEER 3T, depending on scheduling and site availability. The MR scanner will be running the same software version throughout the study.
Data from participants in the Pilot Study will not be included in the analysis of the Main Study.
Data Quality Verification :
All pilot data will be reviewed by Siemens to verify image acquisition quality, completeness, and adherence to the imaging protocol.
Repeatability and reproducibility will be evaluated in the Pilot Study.
Main Study
Participants will be recruited from clinical practices in the Houston, Texas area by hepatologists, gastroenterologists, and other referring clinicians. US (ultrasound) and MRI examinations will be performed across 3 Sponsor imaging centers in the Houston area. All participants will undergo Baseline US (ultrasound) biomarkers (UDFF, pSWE) and MRI biomarkers (MRI-PDFF, MRE) on the same day.
Blinding
Duration of Study Participation
Study Assessments
666 studies on the registry are indexed under Fatty Liver; 188 are open to participants now.
This study's planned enrollment of 524 is above the median of 150 across 207 observational studies indexed under Fatty Liver.
Browse Fatty Liver studies →This is the only study on the registry with Radnet Management, Inc. as lead sponsor.
Compared within Fatty Liver, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Fibrosis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Participants must be fully informed of the potential benefits of approved products and make an informed decision that they prefer to participate in a clinical study. Regulatory, ethical, and study oversight considerations are provided in the protocol.
Participants will be recruited from clinical practices in the Houston, Texas area by hepatologists, gastroenterologists, and other referring clinicians.
Participants will be eligible if they meet ALL inclusion criteria and NONE of the exclusion criteria at Screening.
Enrollment Criteria
Participants will be recruited from clinical practices in the Houston, Texas area by hepatologists, gastroenterologists, and other referring clinicians.
Inclusion Criteria (Pilot Study):
Inclusion Criteria (Main Study):
Exclusion Criteria (Pilot Study, Main Study):
Participants meeting ANY of the following criteria will be excluded:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diagnostic performance of UDFF (ultrasound-derived fat fraction)
Ultrasound criteria associated with elevated liver fat at baseline: UDFF ≥8%
Time frame: Enrollment Day 1 Baseline
Diagnostic performance of Ultrasound pSWE (point shear wave elastography)
Ultrasound criteria consistent with MASH F2-F3 fibrosis at baseline: pSWE ≥7 and \<17 kPa
Time frame: Enrollment Day 1 Baseline
The accuracy of the Ultrasound biomarker pSWE (point shear wave elastography) for monitoring resmetirom treatment response over time.
Percent changes in Ultrasound pSWE from baseline to follow-up period are tested for statistical equivalence.
Time frame: 6 months to 24 months of follow-up period
The accuracy of the Ultrasound biomarker UDFF (ultrasound-derived fat fraction) for monitoring resmetirom treatment response over time.
Percent changes in UDFF from baseline to follow-up period are tested for statistical equivalence
Time frame: 6 months to 24 months of follow-up period
Corresponding percent changes in MRI-PDFF (proton density fat fraction) from baseline to follow- up period are tested for statistical equivalence
MR criteria associated with elevated liver fat at baseline: PDFF ≥8%
Time frame: 6 months to 24 months follow-up period
Corresponding percent changes in MRE (magnetic resonance elastography) from baseline to followup period are tested for statistical equivalence
MR criteria consistent with MASH F2-F3 fibrosis at baseline: MRE ≥3.3 and \<5 kPa
Time frame: 6 months to 24 months follow-up period
Correlation between percent changes in imaging biomarkers for monitoring resmetirom treatment response over time.
Percent changes in UDFF and MRI-PDFF values from baseline to follow-up period and Percent changes in pSWE and MRE values from baseline to follow-up period.
Time frame: 6 months to 24 months follow-up period
To evaluate factors influencing imaging biomarkers MRI-PDFF, MRE, UDFF and pSWE.
• Assessment of the influence of GLP-1 therapy use using a subgroup analysis.
Time frame: Enrollment Day 1 Baseline to 24 months follow-up period
To evaluate factors influencing imaging biomarkers MRI-PDFF, MRE, UDFF and pSWE.
• Assessment of the influence of weight change using a subgroup analysis.
Time frame: Enrollment Day 1 Baseline to 24 months followup period
To evaluate factors influencing imaging biomarkers MRI-PDFF, MRE, UDFF and pSWE.
• Assessment of the association of BMI
Time frame: Enrollment Day 1 Baseline to 24 months follow-up period
To evaluate factors influencing imaging biomarkers MRI-PDFF, MRE, UDFF and pSWE.
• Assessment of the association of MR-R2 (speed of signal delay)
Time frame: Enrollment Day 1 Baseline to 24 months follow-up period.
To evaluate factors influencing imaging biomarkers MRI-PDFF, MRE, UDFF and pSWE.
Assessment of association of laboratory findings
Time frame: Enrollment Day 1 Baseline to 24 months follow-up period
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Oct 2028, 24 months later.
Of 88 non-industry observational studies under Fatty Liver, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 68. This study's planned 24 months is below that.
Counting every sponsor, half of 97 studies reached it within 33 months; a quarter within 20 and three quarters within 68.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.